TriangleAbiraterone acetate (NCT05422911)
Abiraterone acetate trial for Metastatic Cancer (NCT05422911). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult male Veterans with castration-sensitive prostate cancer starting androgen deprivation or who started within 120 days. Prior treatment restrictions apply.
The idea: random assignment compares abiraterone, which reduces androgen production, with enzalutamide or apalutamide, which block androgen receptors. These medicines are taken by mouth. Abiraterone accompanies methylprednisolone or prednisone, depending on its formulation. Androgen deprivation continues unless the testes were surgically removed. Researchers compare tumor growth rates and testosterone levels.
This phase 2 study plans 192 patients. Sun Pharmaceutical sponsors the study; twelve US Veterans Affairs sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.